Patents Examined by Thea D'Ambrosio
  • Patent number: 11406709
    Abstract: Described herein are novel compositions comprising, for example, PDCL3 polypeptides having VEGFR-2 inhibitory activity, inhibitory PDCL3 antibodies and PDCL3-binding fragments thereof, or PDCL3 inhibitory nucleic acid molecules, and methods of their use in anti-angiogenesis and anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, as well as the treatment of those vascular diseases where pathological angiogenesis plays a role, such as in carotid artery disease, macular degeneration, and plaque neovascularization. Also described herein are novel compositions comprising engineered PDCL3 polypeptides having enhanced chaperone activity, recombinant cells comprising such engineered PDCL3 polypeptides having enhanced chaperone activity, and methods thereof for therapeutic protein production and in vitro protein synthesis.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: August 9, 2022
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventor: Nader Rahimi
  • Patent number: 11376309
    Abstract: The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: July 5, 2022
    Assignee: Cerenis Therapeutics Holding S.A.
    Inventors: Jean-Louis Dasseux, Rose Ackermann, Daniela Carmen Oniciu
  • Patent number: 11364278
    Abstract: The present invention relates to compositions and methods for treating autoimmune, microbial, metabolic, neoplastic, and posttraumatic diseases mediated by inflammation in a subject. Compositions and methods including at least one importin beta-selective nuclear transport modifier (NTM) and/or at least one importin alpha-selective NTM, and/or at least one importin alpha-specific NTM, and/or at least one inhibitor of importin alpha and importin beta complex formation may be administered to a subject to modulate the transport of transcription factors, mediated by nuclear import adaptors, into the nucleus of a cell resulting in a decrease or abrogation of inflammation.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: June 21, 2022
    Assignee: VANDERBILT UNIVERSITY
    Inventors: Jack J. Hawiger, Jozef Zienkiewicz
  • Patent number: 11352413
    Abstract: Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD-L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: June 7, 2022
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventors: Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei
  • Patent number: 11325945
    Abstract: The present invention relates to novel short chain peptides of formula (I) which can be useful as a vaccine when in conjugation with suitable immunogenic carrier and suitable adjuvant. These are useful for the treatment for the PCSK9 mediated diseases.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: May 10, 2022
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Mukul Jain, Suresh Giri, Rajesh Bahekar, Gaurav Gupta, Rajendra Chopade
  • Patent number: 11319374
    Abstract: Agents that inhibit the dimerization of a prototypic galectin such as galectin-7 are described. These agents, for example antibodies and peptides, bind to a domain corresponding to residues 13-25, 86-108 and/or 129-135 of human galectin-7. The use of such agents to inhibit a biological, physiological and/or pathological process that involves prototypic galectin dimerization, for example for, the inhibition of galectin-7-mediated apoptosis and the treatment of galectin-7-expressing cancers, is also described.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: May 3, 2022
    Assignee: INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: David Chatenet, Nicolas Doucet, Yves St-Pierre, Maria-Claudia Vladoiu
  • Patent number: 11312756
    Abstract: Compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. Pharmaceutical compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. A method for treating cancer is provided.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: April 26, 2022
    Assignee: The Trustees of Princeton University
    Inventors: A. James Link, Siyan Zhang
  • Patent number: 11306139
    Abstract: The present invention relates to glycosylated immunoglobulin variable domains, and in particular to glycosylated immunoglobulin single variable domains (the latter also being referred to herein by means of the abbreviation “ISF” or “ISVD”). The present invention relates to glycosylated immunoglobulin heavy-chain variable domains (also referred to herein as “VH domains”), and in particular to glycosylated immunoglobulin heavy-chain ISVD's. The invention in particular relates to immunoglobulin (single) variable domains that are glycosylated in such a way that the binding of said immunoglobulin (single) variable domains by so-called “pre-existing antibodies” is prevented and/or reduced (i.e. partially or essentially completely) compared to the same immunoglobulin (single) variable domain without the glycosylation of the invention being present.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: April 19, 2022
    Assignee: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Carlo Boutton
  • Patent number: 11285128
    Abstract: The present application in one aspect provide Fc-containing polypeptide conjugates comprising an Fc-containing polypeptide conjugated to a conjugate moiety, wherein the Fc-containing polypeptide comprises an N-glycosylated Fc region comprising an acceptor glutamine residue flanked by an N-glycosylation site and wherein the conjugate moiety is conjugated to the Fc-containing polypeptide via the acceptor glutamine residue. Also provided are methods of making such Fc-containing polypeptide conjugates by using a wildtype or engineered transglutaminases. Further provided are engineered transglutaminases specifically designed for carrying out such reactions.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: March 29, 2022
    Assignee: CSPC MEGALITH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Sean Hu, Lisha Allen
  • Patent number: 11279943
    Abstract: Provided is a technique for highly expressing a target protein in a plant cell by using a glycosylation domain, a recombinant vector comprising a gene encoding a fusion protein of a glycosylation domain and a target protein, a recombinant cell, a transformed plant, and a method of producing a target protein using these.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: March 22, 2022
    Assignee: BIOAPPLICATIONS INC.
    Inventors: In Hwan Hwang, Hyang Ju Kang
  • Patent number: 11274139
    Abstract: The present invention pertains to inter alia therapeutic delivery vesicles, for instance exosomes or microvesicles, comprising polypeptide constructs, methods for producing said therapeutic delivery vesicles, pharmaceutical compositions and medical uses thereof. The therapeutic polypeptide constructs comprised in the extracellular delivery vesicles enable sequestering target molecules of interest, to treat e.g. neuro-inflammatory diseases and cancer.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: March 15, 2022
    Assignee: Evox Therapeutics Ltd
    Inventors: Samir El Andaloussi, Oscar Wiklander, Joel Nordin, Edvard Smith, Karl-Henrik Grinnemo, Oscar Simonson
  • Patent number: 11266715
    Abstract: The present invention relates to use of a human C3a receptor agonist in the manufacture of a medicament for the treatment or prevention of an ischemic brain injury, wherein the medicament is formulated for intranasal delivery, human C3a receptor agonist for such use, as well as devices for intranasal administration comprising a human C3a receptor agonist and kits comprising such devices.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: March 8, 2022
    Inventors: Marcela Pekna, Milos Pekny, Anna Stokowska
  • Patent number: 11254920
    Abstract: The present invention relates to a factor VII composition having a substantially homogeneous isoelectric point and to a method for formulating such a composition. The present invention also relates to the therapeutic use of a factor VII composition having a substantially homogeneous isoelectric point.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: February 22, 2022
    Assignee: Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventor: Guillaume Chevreux
  • Patent number: 11213565
    Abstract: The present invention relates to a protein derived from lactic acid bacteria and a method for producing the same. The lactic acid bacteria-derived protein of the present invention is a purified protein isolated from lactic acid bacteria (Lactobacillus rhamnosus) having an excellent therapeutic effect against colorectal cancer. It has been demonstrated to have a remarkable effect against colorectal diseases, and thus is expected to be widely used as a natural protein therapeutic agent against colorectal diseases in the medical field.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: January 4, 2022
    Assignee: CELL BIOTECH CO., LTD.
    Inventor: Myung Jun Chung
  • Patent number: 11191806
    Abstract: Field of application: The invention relates to medicine and pharmacy and allows to obtain new pharmaceutical compositions based on polymyxin for the treatment of severe infectious diseases, but not possessing nephrotoxic properties in therapeutic doses. Technical result: New combined dosage forms based on the antibiotic polymyxin with low nephrotoxicity and high activity.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: December 7, 2021
    Inventors: Boris Farber, Ilya Ruvimovich Kleyn, Artur Viktorovich Martynov
  • Patent number: 11185601
    Abstract: The present invention provides peptide conjugates that target an integrin such as ?v?6 integrin. In particular embodiments, the peptide conjugates comprise a moiety such as a PEG moiety, an imaging agent, or a therapeutic agent. The peptide conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue. Compositions and kits containing the peptide conjugates of the present invention are also provided herein.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: November 30, 2021
    Assignee: The Regents of the University of California
    Inventors: Yng Tang, Julie L. Sutcliffe
  • Patent number: 11180529
    Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: November 23, 2021
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Aaron Almeida, Zhen Li, Erik W. Bush, Tao Pei, Agnieszka Glebocka, Anthony Nicholas, Jeffrey Carlson, Matthew Fowler-Watters
  • Patent number: 11141464
    Abstract: The present application belongs to the field of medicine. The present application relates to a GLP-1 polypeptide having GLP-1 receptor agonist activity and the use thereof. The present application further relates to a pharmaceutical composition comprising the GLP-1 polypeptide. In particular, the present application relates to a GLP-1 polypeptide having GLP-1 receptor agonist activity, or a pharmaceutically acceptable salt thereof, characterized in that the GLP-1 polypeptide has a mutation from threonine to proline at the position corresponding to the 13th position of the amino acid sequence of GLP-1.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: October 12, 2021
    Inventors: Liu Jianning, Wang Jingyi
  • Patent number: 11129869
    Abstract: The present invention relates to an ionic complex comprising a cationic polypeptide and an anionic excipient selected from: a PEG-carboxylic acid; a fatty acid having 10 or more carbon atoms; an anionic phospholipid; and a combination thereof. The invention also relates to a pharmaceutical composition comprising the ionic complex of the invention and a pharmaceutically acceptable carrier. The cationic polypeptide of the ionic complex has pharmacological activity and the complex can provide a more desirable pharmacokinetic profile for the cationic polypeptide of the complex as compared to the cationic polypeptide alone following administration. As such, the invention also relates to the use of the ionic complex and pharmaceutical composition comprising same to treat a subject suffering from a disease or disorder that is responsive to the cationic polypeptide of the ionic complex.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 28, 2021
    Assignee: RHYTHM PHARMACEUTICALS, INC.
    Inventors: Shubh Sharma, Leonardus H. T. Van Der Ploeg, Bart Henderson
  • Patent number: 11124557
    Abstract: Provided in the present invention is a PDL-1 molecule. The affinity of the PDL-1 molecule to the PD-1 molecule is at least two times the affinity of the wild-type PDL-1 molecule to the PD-1 molecule. Meanwhile, the PDL-1 molecule of the present invention can effectively improve the killing efficiency of lymphocytes. In addition, the present invention also provides nucleic acids encoding the PDL-1 molecule of the present invention, and a complex of the PDL-1 molecules of the present invention. The PDL-1 molecule of the present invention may be used alone or in combination with other molecules.
    Type: Grant
    Filed: October 9, 2016
    Date of Patent: September 21, 2021
    Assignee: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES
    Inventors: Yi Li, Zhaoduan Liang